阿托伐他汀联合贝那普利对慢性心力衰竭患者的疗效及心功能的影响  

Clinical efficacy and effects of atorvastatin combined with benazepril on cardiac function in patients with chronic heart failure

作　　者：贺继忠 李慧婷[1] HE Jizhong;LI Huiting(Cardiovascular Medicine Department,Yah＇an People＇s Hospital,Yan＇an 716000,China)

机构地区：[1]延安市人民医院心血管内科,陕西延安716000

出　　处：《药物评价研究》2018年第9期1664-1667,共4页Drug Evaluation Research

摘　　要：目的探讨阿托伐他汀联合贝那普利对慢性心力衰竭患者的疗效及对心功能的影响。方法选取延安市人民医院2014年1月—2017年6月收治的慢性心力衰竭患者110例,按治疗方法分成对照组55例、观察组55例。对照组在常规治疗的基础上使用贝那普利治疗,10 mg/次,1次/d。观察组在对照组基础上联合阿托伐他汀治疗,20 mg/次,1次/d,在晚餐后口服。两组疗程均为6个月。比较两组临床疗效、心功能相关指标的变化及不良反应的发生情况。结果观察组临床疗效的总有效率为89.09%(49/55),显著高于对照组的72.73%(40/55),差异有统计学意义(P<0.05)。治疗前两组的左室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)间无显著差异。治疗后两组LVEF均显著降低(P<0.05),对照组LVEDD、LVESD的变化不显著,而观察组的显著降低(P<0.05),且两组间以上指标比较差异显著(P<0.05)。对照组不良反应的发生率是9.09%,观察组是5.45%,两组间无显著差异。结论阿托伐他汀联合贝那普利对于慢性心力衰竭的疗效确切,安全可靠,值得临床应用推广。Objective To explore the clinical efficacy and effects of atorvastatin combined with benazepril on cardiac function in patients with chronic heart failure. Methods Selected 110 patients with chronic heart failure in our hospital from January 2014 to June 2017. All patients were divided into control group and observation group by treatment methods, each of group of 55 cases. The control group was treated with benazepril on the basis of routine treatment. The observation group was treated with atorvastatin on the basis of the control group. The clinical curative effect, changes of cardiac function related indicators and incidence of adverse reactions were compared between the two groups. Results The total effective rate of observation group was 89.09%（49/55）, which was significantly higher than that of control group（72.73%, 40/55）（P〈0.05）. Before treatment, there was no significant difference between LVEF, LVEDD and LVESD of two groups. After treatment, LVEF in both groups were significantly decreased（P〈0.05）, but LVEDD and LVESD in control group were not significantly different, while those in observation group were significantly lower（P〈0.05）. The incidence of adverse reactions was 9.09% in the control group and 5.45% in the observation group, with no significant difference between the two groups. Conclusions Atorvastatin combined with benazepril for the treatment of chronic heart failure is accurate, safe and reliable, it is worth promoting the clinical application.

关 键 词：阿托伐他汀 贝那普利 慢性心力衰竭 

分 类 号：R969.4[医药卫生—药理学]